Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo

Next Previous
Trial Profile

Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION-1
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 30 Jul 2021 Results from ENGAGE, EMERGE, Expedition 1, 2, and 3 and the PRIME study; combining evidence across outcomes and trials using bayesian hierarchical analysis, presented at the Alzheimer's Association International Conference 2021
    • 31 Jul 2020 Results of post hoc analysis from EXPEDITION-1 and EXPEDITION-2 presented at the Alzheimer's Association International Conference 2020
    • 20 Jul 2017 Results evaluating central drug target engagement (TE) and pharmacodynamic (PD) activity of solanezumab in EXPEDITION3 and comparing both to that in the pooled mild AD population from EXPEDITION and EXPEDITION 2 studies, presented at the Alzheimer's Association International Conference 2017
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top